Mizuho Downgrades Chemours to Neutral, Lowers Price Target to $15

Benzinga · 3d ago
Mizuho analyst John Roberts downgrades Chemours (NYSE:CC) from Outperform to Neutral and lowers the price target from $18 to $15.